 |
(+)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride |
|---|---|
| Trade Name | |
| Orphan Indication | C1-inhibitor-dependent angioedema (including prevention and treatment of attacks) |
| USA Market Approval | USA |
| USA Designation Date | 2017-11-01 00:00:00 |
| Sponsor | BioCryst Pharmaceuticals, Inc.;4505 Emperor Blvd, Suite 200200;Durham, North Carolina, 27703 |
